









Markets
/
Stocks
/
nasdaq-hae
/

Haemonetics Corp

HAE

54.040USD

-1.480-2.67%

Close 03/27, 16:00（ET）Quotes delayed by 15 min

2.79BMarket Cap

14.84P/E TTM



Haemonetics Corp

54.040

-1.480-2.67%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Haemonetics Corp

Currency: USD Updated: 2026-03-27

Key Insights

Haemonetics Corp's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 29 out of 208 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 87.50.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Haemonetics Corp's Score

Industry at a Glance

Industry Ranking

29 / 208

Overall Ranking

109 / 4542

Industry

Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Haemonetics Corp Highlights

StrengthsRisks

Haemonetics Corporation is a global healthcare company. The Company is engaged in providing a suite of medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. The Company’s technology addresses various medical markets, including blood and plasma component collection, the surgical suite, and hospital transfusion services. The Company’s Plasma segment includes plasma collection devices and disposables, donor management software and supporting software solutions sold to plasma customers. Its Blood Center segment manufactures and provides customers with its full line of apheresis solutions for automated blood collection. The Company’s Hospital segment consists of Interventional Technologies, which includes Vascular Closure, Sensor Guided Technologies and Esophageal Protection products, and Blood Management Technologies, which includes Hemostasis Management, Cell Salvage and Transfusion Management products.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 16.44% year-on-year.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 1.36B.

Undervalued

The company’s latest PE is 14.84, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 51.51M shares, decreasing 14.21% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 159.00 shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 1.27.

Analyst Rating

Based on 11 analysts

Buy

Current Rating

87.500

Target Price

+54.43%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-27

The current financial score of Haemonetics Corp is 7.52, ranking 68 out of 208 in the Healthcare Equipment & Supplies industry. Its financial status is stable, and its operating efficiency is average. Its latest quarterly revenue reached 338.97M, representing a year-over-year decrease of 2.75%, while its net profit experienced a year-over-year decrease of 19.33%.

Score

Industry at a Glance

Previous score

7.52

Change



Financials

7.26

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.14

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

7.86

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

8.16

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.18

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Haemonetics Corp's Company Valuation

Currency: USD Updated: 2026-03-27

The current valuation score of Haemonetics Corp is 7.71, ranking 65 out of 208 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is 14.84, which is 224.61% below the recent high of 48.18 and 2.24% above the recent low of 14.51.

Score

Industry at a Glance

Previous score

7.71

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 29/208

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-27

The current earnings forecast score of Haemonetics Corp is 7.82, ranking 114 out of 208 in the Healthcare Equipment & Supplies industry. The average price target is 88.00, with a high of 108.00 and a low of 62.00.

Score

Industry at a Glance

Previous score

7.82

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 11 analysts

Buy

Current Rating

87.500

Target Price

+54.43%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

115

Total

Median

Average

Company name

Ratings

Analysts

Haemonetics Corp

HAE

Medtronic PLC

MDT

Stryker Corp

SYK

Dexcom Inc

DXCM

Zimmer Biomet Holdings Inc

ZBH

Abbott Laboratories

ABT

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-27

The current price momentum score of Haemonetics Corp is 6.53, ranking 112 out of 208 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 62.13 and the support level at 49.92, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.56

Change

-0.03

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.936

Sell

RSI(14)

21.188

Sell

STOCH(KDJ)(9,3,3)

5.269

Oversold

ATR(14)

1.881

Low Volatility

CCI(14)

-172.897

Sell

Williams %R

98.446

Oversold

TRIX(12,20)

-0.418

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

56.122

Sell

MA10

57.736

Sell

MA20

60.351

Sell

MA50

62.602

Sell

MA100

70.091

Sell

MA200

65.289

Sell

Institutional Confidence

Currency: USD Updated: 2026-03-27

The current institutional shareholding score of Haemonetics Corp is 10.00, ranking 1 out of 208 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 110.83%, representing a quarter-over-quarter decrease of 4.99%. The largest institutional shareholder is The Vanguard, holding a total of 4.75M shares, representing 10.22% of shares outstanding, with 3.51% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

5.30M

-4.80%

The Vanguard Group, Inc.

Star Investors

4.82M

-2.40%

Neuberger Berman, LLC

3.67M

-14.19%

AQR Capital Management, LLC

2.13M

+372.82%

State Street Investment Management (US)

1.80M

-4.42%

Geode Capital Management, L.L.C.

1.20M

-3.31%

Risk Assessment

Currency: USD Updated: 2026-03-27

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Haemonetics Corp is 6.94, ranking 49 out of 208 in the Healthcare Equipment & Supplies industry. The company's beta value is 0.34. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.